Zydus announces Phase I trials of ZYIL1
NEW DELHI: Ahmedabad- based pharmaceutical company Zydus has announced that it has received permission to initiate the Phase 1 clinical trial of ZYIL1, a novel oral small molecule NLRP3 inhibitor candidate. NLRP3 inflammasomes are involved in the inflammation process by production and release of pro-inflammatory cytokines IL-1β and IL-18. This harmful inflammation within the body […]
Zydus receives approval from DCGI to commence Phase III clinical trials with Pegylated Interferon alpha-2b in India
NEW DELHI: Zydus Cadila has announced that it had received an approval from the Drugs Controller General of India (DCGI) to start the Phase 3 clinical trial in CoVID-19 patients with its biological therapy, Pegylated Interferon alpha-2b, ‘PegiHepTM’. The trials which will commence in December will be conducted on 250 patients across 20-25 centres in […]